Alnylam Pharmaceuticals
ALNY
249 hedge funds and large institutions have $4.11B invested in Alnylam Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 110 increasing their positions, 61 reducing their positions, and 37 closing their positions.
104% more call options, than puts
Call options by funds: $68.7M | Put options by funds: $33.7M
80% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 61
2% less funds holding
Funds holding: 255 → 249 (-6)
8% less capital invested
Capital invested by funds: $4.45B → $4.11B (-$340M)
11% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 37
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$171M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$159M |
| 3 |
DM
Deerfield Management
New York
|
+$21.2M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$20.3M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$86M |
| 2 |
VAM
Visium Asset Management
New York
|
-$49.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$46M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$22.2M |
| 5 |
Morgan Stanley
New York
|
-$12.8M |
ALNY Hedge Fund Activity: Q2 2016 in Review
249 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2016, worth a combined $4.11B — down 7.6% from $4.45B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ALNY and 33 opened new positions — a net loss of 4 holders — while 61 trimmed existing stakes and 110 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $171M. The largest seller was Capital World Investors, cutting an estimated $86M.
- 249 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2016, down from 255 in Q1 2016.
- Funds reported $4.11B of Alnylam Pharmaceuticals stock for Q2 2016, down 7.6% quarter-over-quarter.
- 33 funds opened new Alnylam Pharmaceuticals positions in Q2 2016 and 37 closed out, a net change of -4 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2016 was T. Rowe Price Associates, an estimated $171M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2016 was Capital World Investors, an estimated $86M sold.
Based on aggregated 13F filings for Q2 2016.